Insecticides India reports Rs 67.61 cr operating profit in Q1FY27
Operations led earnings, while the presentation highlighted 70,000 MT/KL of formulation capacity and expansion at Dahej and Sotanala.
Filed 11 Aug 2026, 14:47 IST · INSECTICID (INSECTICID)
Key takeaways
- Consolidated Q1FY27 operating profit was Rs 67.61 cr at an 11.06% operating margin.
- Other income of Rs 5.61 cr was modest beside Rs 67.61 cr operating profit, so reported earnings were led by operations.
- The presentation said annual formulation capacity stands at 70,000 MT/KL, with expansion space at Dahej and an upcoming plant at Sotanala.
Operating profit was the main earnings source
The consolidated quarter generated Rs 67.61 cr of operating profit on revenue of Rs 611.52 cr, resulting in an 11.06% operating margin. Depreciation of Rs 9.71 cr and interest of Rs 4.69 cr reduced operating profit to Rs 58.82 cr of profit before tax.
Other income had a limited role in reported profit
Other income was Rs 5.61 cr, well below operating profit of Rs 67.61 cr, indicating that earnings were primarily generated by the operating business. A 25.41% tax rate reduced profit before tax of Rs 58.82 cr to net profit of Rs 43.87 cr.
Capacity and product development remain central to the business plan
The presentation said the company has annual formulation capacity of 70,000 MT/KL. It also said expansion space is available at Dahej and that a plant at Sotanala is upcoming, while Chopanki and Dahej have been expanded for technical and formulation manufacturing. The presentation further said the company is developing new-generation formulations, biopesticides, fertilizers and nanotechnology products.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹612 cr |
| Other income | ₹6 cr |
| Expenses | ₹544 cr |
| Operating profit | ₹68 cr |
| Operating margin (%) | 11.06% |
| Interest | ₹5 cr |
| Depreciation | ₹10 cr |
| Profit before tax | ₹59 cr |
| Tax | ₹15 cr |
| Net profit | ₹44 cr |
| EPS (₹) | ₹15.08 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Expansion
- The company has 70,000 MT/KL of annual formulation capacity.
- The company has expansion space available at Dahej and an upcoming plant at Sotanala.
- The company expanded its Chopanki and Dahej plants for technical and formulation manufacturing.
New initiatives
- The company is developing new-generation formulations through its R&D infrastructure.
- The company is developing new biopesticides and fertilizers.
- The company is developing nanotechnology products.
- The company implemented CRM platforms called IIL 360, IIL Pariwar and IIL Humsafar.
- IIL Foundation expanded Project Green with Miyawaki plantations across four locations in FY26.
What to watch
- Whether consolidated operating margin holds at 11.06%.
- Whether revenue builds on the Rs 611.52 cr reported in Q1FY27.
- Progress on the upcoming Sotanala plant alongside the cited 70,000 MT/KL annual formulation capacity.